Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 9, 1996, Pages 1156-1162

  De Maat, Moniek P M ^a,b   De Bart, Anton C W ^a   Hennis, Bart C ^a   Meijer, P ^a   Havelaar, Adrie C ^a   Mulder, Paul G H ^b   Kluft, Cornelis ^a  

^a TNO   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

C reactive protein; DNA polymorphism; fibrinogen; plasminogen activator inhibitor; tissue type plasminogen activator

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DNA POLYMORPHISM; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMATOLOGICAL PARAMETERS; HUMAN; MALE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 0029757371     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.9.1156     Document Type: Article

References (42)

1. Meade TW, Mellows S, Brozovic M. Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533-537.
2. Kannell WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA, 1987;258:1183-1186.
3. Yarnell JWG, Fehily AM, Milbunk J, Kubicki AJ, Eastham R. Hayes TM. Determinants of plasma lipoproteins and coagulation factors in men from Caerphilly, South Wales. J Epidemiol Community Health. 1983;37:137-140.
4. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-505.
5. Haverkate F. Thrombosis and disabilities. In: Baya C, ed. Advances in Medical Biology. Amsterdam, Netherlands: IOS Press; 1994:81-103.
6. Stone MC, Thorpe JM. Plasma fibrinogen: a major coronary risk factor. J R Coll Gen Pract. 1985;35:565-569.
7. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men, Anerioscler Thromb. 1994;14:54-59.
8. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
9. Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J. 1991;12:157-161.
10. Gram J, Jespersen J. A selective depression of tissue plasminogen activator (t-PA) activity in euglobulin characterizes a risk group among young survivors of acute myocardial infarction. Thromb Haemost. 1987;57:137-139.
11. Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
12. Meade TW, Chakrabarti RR, Haines AP, North WRS, Stirling Y. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. Br Med J. 1979;1:153-156.
13. Meade TW, North WRS. Population based distribution of haemostatic variables. Br Med Bull. 1977;33:283-288.
14. Balleisen L, Bailey J, Epping PH, Schulte H, van de Loo J. Epidemiology study on factor VII, factor VIII and fibrinogen in an industrial population, I: baseline data on the relation to age, gender, body weight, smoking, alcohol, pill using and menopause. Thromb Haemost. 1985;54:475-479.
15. Siegert G, Bergmann S, Jaross W. Relationship of plasminogen activator inhibitor activity and tissue-type plasminogen activator concentration with age, sex, risk factors for coronary heart disease and life style. Fibrinolysis. 1994;4(suppl 2):34-36.
16. Haire WD, Goldsmith JC, Rasmussen J. Abnormal fibrinolysis in healthy male cigarette smokers: role of plasminogen activator inhibitors. Am J Hematol. 1988;31:36-40.
17. Hashimoto Y, Kobayashi A, Yamazaki N, Sugawara Y, Takada Y, Takada A. Relationship between age and plasma t-PA, PA-inhibitor and PA activity. Thromb Res. 1987;46:625-633.
18. Aillaud MF, Pignol F, Alessi MC, Harle JR, Escande M, Mongin M, Juhan-Vague I. Increase in plasma concentration of plasminogen activator inhibitor, fibrinogen, von Willebrand factor VIII, protein C and in erythrocyte sedimentation rate with age. Thromb Haemost. 1986;55:330-332.
19. Kruithof EK, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, Welti H, Bachmann F. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood. 1987;69:460-466.
20. Kluft C, Veenstra J, Schaafsma G, Pikaar NA. Regular moderate wine consumption for five weeks increases plasma activity of the plasminogen activator inhibitor-1 (PAI-1) in healthy young volunteers. Fibrinolysis, 1990;4(suppl 2):69-70.
21. Müllertz A, Hølmer G, Grøndahl-Hansen J. Increased concentration of plasminogen activator inhibitor type-1 in plasma after intake of fish oil. Fibrinolysis. 1990;4(suppl 2):86-88.
22. Emeis JJ, Houwelingen AC, van den Hoogen CM, Hornstra G. A moderate fish intake increases plasminogen activator inhibitor type1 in human volunteers. Blood. 1989;74:233-237.
23. De Geus EJC, Kluft C, De Bart ACW, van Doornen LJP. The effects of exercise training on plasminogen activator inhibitor activity, body fat, blood pressure and the lipid profile. Med Sci Sports Exerc. 1992;24:1210-1219.
24. Verheijen JH, Rijken DC, Chang GTG, Preston FE, Kluft C. Modulation of rapid plasminogen activator inhibitor in plasma by stanazolol. Thromb Haemost. 1984;51:396-397.
25. Andreotti F, Davies GJ, Hackett D, Khan MI, De Bart ACW, Dooijewaard G, Maseri A, Kluft C. Circadian variation of fibrinolytic factors in normal human plasma. Fibrinolysis. 1988;2(suppl 2):90-92.
26. Das I. Raised C-reactive protein levels in serum from smokers. Clin Chim Acta. 1985;153:9-13.
27. Allen RA, Kluft C, Brommer EJP. Effect of chronic smoking on fibrinolysis. Arteriosclerosis. 1985;5:443-452.
28. Dugué B, Leppänen EA, Teppo AM, Fyhrquist F, Gräsbeck R. Effects of psychological stress on plasma interleukins-1 beta and 6, Creactive protein, tumour necrosis factor alpha, anti-diuretic hormone and serum Cortisol. Scand J Clin Lab Invest. 1993;53:555-561.
29. Thomas EA, Green FR, Kelleher CH, Wilkes HC, Brennan PJ, Meade TW, Humphries SE. Variation in the promoter region of the β fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb Haemost. 1991;65:487-490.
30. Humphries SE, Cook M, Dubowitz M, Stirling Y, Meade TW. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet. 1987;1:1452-1455.
31. Dawson SJ, Hamsten A, Wiman B, Henney AM, Humphries SE. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb. 1991;1:183-190.
32. Dawson SJ, Hamsten A, Wiman B, Henney AM, Humphries SE. Genetic variation at the plasminogen activator inhibitor-1 (PAI-1) locus, Fibrinolysis. 1990;4(suppl 2):51-53.
33. Kluft C, Verheijen JH, Blood collection and handling procedures. Fibrinolysis. 1990;4(suppl 2):155-161.
34. Von Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol. 1957;17:237-246.
35. Astrup T, Brakman P, Nissen U. The estimation of fibrinogen: a revision. Scand J Clin Invest. 1965;17:57-65.
36. Verheijen JH, Chang GTG, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost. 1984;51:392-395.
37. Klinger K, Winqvist R, Riccio A, Andreasen PA, Sartorio R, Nielsen LS, Stuart N, Stanislovitis P, Watkins P, Douglas R, Grzeschik K-H, Alitalo K, Blase F, Danø K. Plasminogen activator inhibitor type-1 is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci U S A. 1987;84:8548-8552.
38. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci. 1989;27:409-437.
39. Marekmann P, Sandström B, Jespersen J. The variability of and associations between measures of blood coagulation, fibrinolysis and blood lipids. Atherosclerosis. 1992;96:235-244.
40. Thompson SG, Martin JC, Meade TW. Sources of variability in coagulation factor assays. Thromb Haemost. 1987;58:1073-1077.
41. Clark GH, Fraser CG. Biological variation of acute phase protein. Ann Clin Biochem. 1993;30:373-376.
42. Rosenson RS, Tangney CC, Hafner JM. Intraindividual variability of fibrinogen levels and cardiovascular risk profile. Arterioscler Thromb. 1994;14:1928-1932.